708 related articles for article (PubMed ID: 36276132)
1. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia.
Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F
Front Oncol; 2022; 12():966920. PubMed ID: 36276132
[TBL] [Abstract][Full Text] [Related]
2. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia.
Zhu Y; He J; Li Z; Yang W
BMC Bioinformatics; 2023 Feb; 24(1):37. PubMed ID: 36737692
[TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-related lncRNAs forecast the prognosis of acute myeloid leukemia.
Zhang T; Liao D; Hu Y
Transl Cancer Res; 2023 May; 12(5):1175-1195. PubMed ID: 37304546
[TBL] [Abstract][Full Text] [Related]
4. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
Xu M; Mu J; Wang J; Zhou Q; Wang J
Front Oncol; 2022; 12():961213. PubMed ID: 35965536
[TBL] [Abstract][Full Text] [Related]
5. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
6. Cuproptosis-related lncRNA signature as a prognostic tool and therapeutic target in diffuse large B cell lymphoma.
Bai X; Lu F; Li S; Zhao Z; Wang N; Zhao Y; Ma G; Zhang F; Su X; Wang D; Ye J; Li P; Ji C
Sci Rep; 2024 Jun; 14(1):12926. PubMed ID: 38839842
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of cuproptosis-associated LncRNAs predictive value and related CeRNA network in acute myeloid leukemia.
Cao C; Wang T; Luo Y; Zhang Y; Dai YY; Shen Y
Heliyon; 2023 Dec; 9(12):e22532. PubMed ID: 38058427
[TBL] [Abstract][Full Text] [Related]
8. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
9. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation.
Zhou L; Cheng Q; Hu Y; Tan H; Li X; Wu S; Zhou T; Zhou J
Front Oncol; 2022; 12():1030802. PubMed ID: 36620545
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma.
Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B
Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235
[TBL] [Abstract][Full Text] [Related]
11. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; AbrĂ£o FC; Puthamohan VM; Liu L; Jiang T
Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
[TBL] [Abstract][Full Text] [Related]
12. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients.
Jiang ZR; Yang LH; Jin LZ; Yi LM; Bing PP; Zhou J; Yang JS
Front Oncol; 2022; 12():988680. PubMed ID: 36203428
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
[TBL] [Abstract][Full Text] [Related]
15. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
16. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
Front Genet; 2023; 14():1056000. PubMed ID: 36845390
[No Abstract] [Full Text] [Related]
17. Cuproptosis-Related Genes MTF1 and LIPT1 as Novel Prognostic Biomarker in Acute Myeloid Leukemia.
Li Y; Kan X
Biochem Genet; 2024 Apr; 62(2):1136-1159. PubMed ID: 37561332
[TBL] [Abstract][Full Text] [Related]
18. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
19. Signature of seven cuproptosis-related lncRNAs as a novel biomarker to predict prognosis and therapeutic response in cervical cancer.
Liu X; Zhou L; Gao M; Dong S; Hu Y; Hu C
Front Genet; 2022; 13():989646. PubMed ID: 36204323
[No Abstract] [Full Text] [Related]
20. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer.
Ren L; Yang X; Wang W; Lin H; Huang G; Liu Z; Pan J; Mao X
Front Genet; 2023; 14():1096783. PubMed ID: 36911392
[No Abstract] [Full Text] [Related]
[Next] [New Search]